Literature DB >> 8186951

The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology.

M I Papp1, P L Lantos.   

Abstract

In this study a semiquantitative mapping of oligodendroglial cytoplasmic inclusions (GCIs), a feature of oligodendroglial degeneration in multiple system atrophy (MSA), was undertaken by means of a sensitive silver technique in 14 brains and 11 spinal cords of patients with various combinations of striatonigral degeneration, olivopontocerebellar atrophy and autonomic failure. The results show a system-bound extensive degeneration of interfascicular, perineuronal and perivascular oligodendrocytes. Oligodendroglial cytoplasmic inclusion-rich structures occur in the supra-segmental motor systems (primary motor and higher motor areas of cerebral cortex, 'pyramidal', 'extrapyramidal' and cortico-cerebellar systems), in the supraspinal autonomic systems and in their targets. In contrast, the visual and auditory pathways, olfactory structures, somatosensory systems, association and limbic cortical areas and subcortical limbic structures contain no or only a few GCIs. Comparison of the severity of oligodendroglial degeneration (GCI-density) with that of the neuronal alterations (neuronal cytoplasmic and nuclear inclusions, degenerated neuronal processes and loss of nerve cells) indicates a striking preponderance of oligodendroglial degeneration and that degeneration neither of axons, nor of neuronal cell bodies is a prerequisite of the development of GCIs. It also suggests that inclusion-bearing oligodendroglial degeneration may cause or contribute to the manifestation of clinical symptomatology in structures with GCI accumulation but without convincing neuronal alterations, i.e. cerebral motor cortical areas and reticular formation of the lower brainstem, both previously thought to be spared in MSA.

Entities:  

Mesh:

Year:  1994        PMID: 8186951     DOI: 10.1093/brain/117.2.235

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  91 in total

Review 1.  Multiple system atrophy: pathophysiology and management.

Authors:  G K Wenning; S Braune
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Differential involvement of the periaqueductal gray in multiple system atrophy.

Authors:  Eduardo E Benarroch; Ann M Schmeichel; Phillip A Low; Joseph E Parisi
Journal:  Auton Neurosci       Date:  2010-08-21       Impact factor: 3.145

3.  A novel computer-assisted image analysis of [123I]β-CIT SPECT images improves the diagnostic accuracy of parkinsonian disorders.

Authors:  Georg Goebel; Klaus Seppi; Eveline Donnemiller; Boris Warwitz; Gregor K Wenning; Irene Virgolini; Werner Poewe; Christoph Scherfler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-21       Impact factor: 9.236

4.  Glial α-synuclein promotes neurodegeneration characterized by a distinct transcriptional program in vivo.

Authors:  Abby L Olsen; Mel B Feany
Journal:  Glia       Date:  2019-07-03       Impact factor: 7.452

5.  Treatment of Spinocerebellar Ataxia With Mesenchymal Stem Cells: A Phase I/IIa Clinical Study.

Authors:  Yun-An Tsai; Ren-Shyan Liu; Jiing-Feng Lirng; Bang-Hung Yang; Chin-Hao Chang; Yi-Chen Wang; Yu-Shan Wu; Jennifer Hui-Chun Ho; Oscar K Lee; Bing-Wen Soong
Journal:  Cell Transplant       Date:  2017-02-14       Impact factor: 4.064

Review 6.  Multiple system atrophy: clues from inclusions.

Authors:  R Castellani
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

7.  Orthostatic hypotension is differentially associated with the cerebellar versus the parkinsonian variant of multiple system atrophy: a comparative study.

Authors:  Gregor Karl Wenning; Roberta Granata; Florian Krismer; Susanne Dürr; Klaus Seppi; Werner Poewe; Katharine Bleasdale-Barr; Christopher J Mathias
Journal:  Cerebellum       Date:  2012-03       Impact factor: 3.847

8.  Insulin resistance and exendin-4 treatment for multiple system atrophy.

Authors:  Fares Bassil; Marie-Hélène Canron; Anne Vital; Erwan Bezard; Yazhou Li; Nigel H Greig; Seema Gulyani; Dimitrios Kapogiannis; Pierre-Olivier Fernagut; Wassilios G Meissner
Journal:  Brain       Date:  2017-05-01       Impact factor: 13.501

Review 9.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

10.  Targeted overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure.

Authors:  Sylvia Stemberger; Werner Poewe; Gregor K Wenning; Nadia Stefanova
Journal:  Exp Neurol       Date:  2010-05-21       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.